New standards of care for NDMM patients not eligible for transplant
|
|
- Rhoda Wilcox
- 5 years ago
- Views:
Transcription
1 New standards of care for NDMM patients not eligible for transplant Thierry FACON, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France
2 Epidemiology of Elderly Changing demographics Increase in life expectancy Aging of the population Increase in the number of elderly 30, World population: % of people , ,5 18,8 22,9 16,3 18,8 21,1 20,1 16,2 19, , 12,1 12, 13,3 11,1 7,5 3,4 4,4 6,7 7, 6,8 0, Africa Asia Europe Latin Am/ Caribbean Northen Am Oceania 65+ in the United States: Census.gov; U.S (June 2014). Census Bureau, 2012b; International Data Base
3 New cases (%) Multiple Myeloma affects primarily elderly patients SEER: New MM Cases by Age Group 40, 30, 23, 27,7 24,7 Myeloma is most frequently diagnosed among people aged , 10, 0, 11,4 9,5 3,1 0, 0,6 < > 84 Median age at diagnosis 69 Age Available from Accessed on 06/2014.
4 ESMO Guidelines 2017 Eligibility for ASCT Yes Induction: 3-drug regimens VTD VCD RVD PAD No First option: VMP, Rd, VRD Second option: VCD, MPT Other options: BP, CTD, MP 200 mg/m 2 Melphalan followed by ASCT Maintenance Lenalidomide FRONTLINE THERAPY. ESMO guidelines. Moreau, et al. Ann Oncol. 2017, in press. Courtesy of Dr. Moreau, April 2017.
5 MPT Becomes a Standard of Care Facon T, et al. Lancet. 2007;370: Fayers PM, et al. Blood. 2011;118:
6 VMP Becomes a Standard of Care San Miguel JF, et al. N Engl J Med. 2008;359:
7 Patients without event (%) Patients without event (%) VMP becomes a standard of care; VISTA Trial: Final analysis RR (CR) (%): 71(30) vs. 35(4) TTP VMP MP OS VMP: 24.0 months MP: 16.6 months, P < Time (months) 20 0 Median follow-up 60 months Median OS: VMP: 56m MP: 43m, P = Time (months) San Miguel et al. JCO 2013; 31(4):
8 RANDOMIZATION 1:1:1 (N = 1623) PD or Unacceptable Toxicity PD, OS, and Subsequent anti-mm Tx Rd becomes a standard of care IFM MM-020- FIRST: Study Design Screening Active Tx + PFS Follow-Up Phase LT Follow-Up Stratification: Age ( 75 vs > 75 yrs), country, and ISS stage (I/II vs III) Arm A Rd Continuous (n = 535) LEN + LoDEX: Continuously LENALIDOMIDE 25 mg days 1-21/28 LoDEX 40 mg days 1, 8, 15,22/28 Thromboprophylaxis was mandatory Arm B Rd18 (n = 541) LEN + LoDEX: 18 Cycles (72 weeks) LENALIDOMIDE 25 mg days 1-21/28 LoDEX 40 mg days 1, 8, 15, 22/28 Data cutoff: January 21, 2016 Arm C MPT (n = 547) MEL + PRED + THAL 12 Cycles (72 weeks) MELPHALAN 0.25 mg/kg days 1-4/42 PREDNISONE 2 mg/kg days 1-4/42 THALIDOMIDE 200 mg days 1-42/42 Pts aged > 75 yrs: LoDEX 20 mg days 1, 8, 15, 22/28; THAL 100 mg days 1-42/42; MEL 0.2 mg/kg days 1-4 FIRST, Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide; ISS, International Staging System; LoDex, low-dose dexamethasone; LT, long-term; MM, multiple myeloma; OS, overall survival; PD, progressive disease; PFS, progression-free survival; pts, patients; Tx, treatment. Benboubker L, et al. N Engl J Med. 2014;371:
9 Survival Probability Survival Probability Progression-Free Survival by Response Median PFS was prolonged in patients who responded to Rd continuous vs MPT and Rd18, particularly in those who achieved a deeper response (CR/VGPR) PFS (CR/VGPR) Median 4-year PFS, PFS, % mos Rd cont (n = 260) Rd18 (n = 255) MPT (n = 167) year PFS PFS ( PR) Median PFS, mos 4-year PFS, % Rd cont (n = 432) Rd18 (n = 425) MPT (n = 369) year PFS 53.8% % % HR (95% CI) Rd continuous vs MPT: 0.52 ( ), P < % Progression-Free Survival (Months) HR (95% CI) Rd continuous vs MPT: 0.65 ( ),P < % 16.0% Progression-Free Survival (Months) CR, complete response; HR, hazard ratio; MPT, melphalan, prednisone, thalidomide; PFS, progression-free survival; PR, partial response; Rd continuous, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; VGPR, very good partial response.
10 Survival Probability Final Analysis of Overall Survival From the First Trial The pre-specified final OS analysis for the primary comparison showed that Rd continuous significantly extended OS vs MPT year OS 59.0% 58.0% Median OS, 4-yr OS, mos % Rd continuous Rd MPT % HR (95% CI) Rd continuous vs MPT: 0.78 ( ), P = Overall Survival (Months) HR, hazard ratio; MPT, melphalan, prednisone, thalidomide; OS, overall survival; Rd continuous, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles.
11 SWOG S0777: Study Design Eight 21-day Cycles of VRd Randomization N = 525 Stratification: ISS (I, II, III) Intent to progression (yes/no) Bortezomib 1.3/mg 2 IV Days 1, 4, 8, and 11 Lenalidomide 25 mg/day PO Days 1-14 Dexamethasone 20 mg/day PO Days 1, 2, 4, 5, 8, 9, 11, 12 Six 28-day Cycles of Rd After induction Rd Maintenance Until PD, Toxicity or Withdrawal Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO days 1, 8,15, 22 Lenalidomide 25 mg/day PO Days 1-21 Dexamethasone 40 mg/day PO Days 1, 8, 15, 22 All patients received aspirin 325mg/day VRd patients received HSV prophylaxis HSV, herpes simplex virus; ISS, international staging system; PD, progressive disease; Rd, lenalidomide plus low dose dexamethasone; VRd, bortezomib, lenalidomide and dexamethasone. Durie et al. Lancet 2017;389:
12 Patients (%) Patients (%) SWOG S0777: PFS and OS by Assigned Treatment Arm PFS by assigned treatment arm OS by assigned treatment arm Events/N Median in months VRd 137/ (39, 52) Rd 166/ (25, 39) Events/N Median in months VRd 76/ (66, -) Rd 100/ (56, -) HR = (0.560, 0.906)* Log-rank P value = (one sided)* VRd Rd HR = (0.516, 0.973)* Log-rank P value = (two sided)* VRd Rd Months from registration Months from registration * Stratified HR, hazard ratio; OS, overall survival; PFS progression free survival; Rd, lenalidomide plus low dose dexamethasone; VRd, bortezomib, lenalidomide and dexamethasone. Durie et al. Lancet 2017;389:
13 Phase 3 Rd-based Continuous Studies for Elderly Patients NCT NCT NCT Elotuzumab Ixazomib Daratumumab Rd R: 25 mg PO ; D1 21 DEX: 40 mg PO ; D1, 8, 15 & d cycles until PD ELO-Rd ELO: 10 mg/kg; D1, 8, 15 & 22 (cycles 1 2); D1 & 15 (cycles 3 18); 20 mg/kg on D1 (cycles 19) R: 25 mg, D1 21 Rd R: 25 mg PO ; D1 21 DEX: 40 mg PO ; D1, 8, 15 & d cycles/18 mos Ixazomib-Rd Ixazomib: 4 mg R: 25 mg DEX: 40 mg; D1, 8, 15 & d cycles/18 mos Rd R: 25 mg PO ; D1 21 DEX: 40 mg PO ; D1, 8, 15 & d cycles until PD DARA-Rd DARA: 16 mg/kg q1wk for 8 wks; q2wk for 16 wks; q4wk thereafter R: 25 mg PO d; D1 21 DEX: 40 mg D1, 8, 15 & 22 (cycles 1 2); D1 & 15 (cycles 3 18); D1 (cycles 19) DEX Discontinued DEX Discontinued DEX: 40 mg PO d; D1, 8, 15 & d cycles, until PD Placebo + R Ixazomib+ R R 10 mg Until PD Ixazomib: 3 mg R: 10 mg Until PD Primary endpoint for all studies is PFS 1. NCT NCT NCT
14 But the upcoming (academic) studies will be Risk stratified and Response adapted A new generation of clinical trials. Courtesy Dr Faith Davies, modified
15 Asessment of fitness and frailty is relevant for optimal treatment selection
16 Stratification of Myeloma Patients; IMWG frailty score PATIENT STATUS ASSESSMENT Age (score 0 1 2) Charlson (score 0 1) ADL (score 0 1) IADL (score 0 1) FIT INTERMEDIATE FRAIL Additive total score = 0 Additive total score = 1 Additive total score 2 Full-dose Full-dose Reduced dose TRIPLET REGIMENS VMP MPT DOUBLET REGIMENS Rd Vd Doublet regimens rd vd Palumbo A et al, Blood 25(13): , 2015
17 MM Frailty Score: long-term outcome Overall Survival Progression-free Survival yrs P-value Fit 84% - Intermediate 76% Frail 57% < Months Cumulative Incidence Non-hematologic mo P-value yrs P-value Fit 48% - Intermediate 41% Frail 33% < Months Cumulative Incidence Drug mo P-value 0.50 Fit 22% - Intermediate 26% Frail 34% < Fit 16% - Intermediate 21% Frail 31% < Months Months Palumbo A et al, Blood 25(13): , 2015
18 IFM Revised Frailty Algorithm with ECOG Category 75 years years > 80 years Charlson 1 Charlson > 1 ECOG =0 ECOG=1 ECOG 2 Score Sum of Scores = 0 or 1 Sum of Scores >=2 NON-FRAIL FRAIL
19 Survival probability Survival probability PFS and OS by Frailty Level in the FIRST study N at risk Non-frail Frail Product-limit survival estimates with number of subjects at risk Subjects Events Censored Survival 95% CL Non-frail Frail censored Log rank P< PFS (months) Non-frail Frail N at risk Non-frail Frail Product-limit survival estimates with number of subjects at risk + censored Log rank P< Non-frail Frail Subjects Events Censored Survival 95% CL Non-frail Frail OS (months)
20 Conclusions VMP, Rd, and VRD are standards of care for newly diagnosed Transplant ineligible patients with MM Assessment of fitness and frailty is relevant for optimal treatment selection - the new generation of (academic) clinical studies in elderly patients will likely differentiate fit vs.frail elderly patients (risk stratification), and some will implement response adapted therapy 4 drug combination regimens (ImiD-PI-CD38Mab-Dex) will likely be suitable for fit elderly, and the need for ASCT in elderly may become uncertain. Frail elderly patients still have a poor clinical outcome and may benefit from an ImiD (or PI) + CD38Mab gentle regimen
21
22 A spanish study for fit elderly NDMM patients; GEMFIT2016 NDMM patients NSCTC >65 y n= 462 elderly Fit Patients ARM 1 VMP N=154 Mel: 9mg/m 2 D1-4 Pred: 60mg/m 2 D1-4 BTZ: 1.3mg/m 2 D1, 8,15,22 ª One 6 week cycle followed by eight 4-week cycle N=159 ARM 2a KRd.N=154 CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, day cycles (R1) Induction 18 cycles N=159 ARM 2b KRD- DARA n=154 Rd LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Nine 28-day cycles CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg IV Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18 Consolidation RdDara LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4 Four 28-day cycles Directly to the R2 maintenance phase MRD+ MRD- (R2) Maintenance No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion * * MRD 9 cy MRD 18 cy MRD 22 cy Primary endpoint immonuphenotypic complete response Secondary exploratory outcome: PFS Courtesy of Dr MV Mateos
23 RANDOMIZATION 1:2 PD or Unacceptable Toxicity PD, OS and Subsequent anti-mm Tx A french study for frail elderly NDMM patients; IFM A dexamethasone sparing study Active Treatment + PFS Follow-up Phase LT Follow-Up 2 Arm A R-DaraSC LEN + Dara SC continuously: LENALIDOMIDE 25mg D1-21/28 DARATUMUMAB SC 1800 mgsc Q1Wk for 8 weeks 1800 mg SC Q2Wk for 16 weeks 1800 mg SC Q4Wk thereafter 1 Arm B Rd LEN + Lo-DEX continously: LENALIDOMIDE 25mg D1-21/28 Lo-DEXAMETHASONE 20mg D1,8,15 & 22/28 Randomization will be stratified by International Staging System (I vs II vs III) and age (<80 vs 80 In Arm A Low Dose Dex (20mg/week) during Cycle 1 and 2 then Methylprednisolone (with SC Dara)
24 What about ASCT in Elderly patients? Do we need a new Transplant Study in Elderly Fit MM patients? If yes, is it still possible? Yes - No clear answer on the benefit of ASCT in Elderly - No randomized study in the era new agents (also considering that anti CD38 will provide additional clinical benefit) No - IFM 2009 and EMN studies positive but not sure ALL young pts benefit from ASCT - The PFS benefit in young pts is 14mo. and will be likely less in elderly - Control Arm will be excellent with a Imid PI - CD38 Dex regimen (median PFS # 50 mo?) - Risk will overweight the benefit (esp for pts y)
25 Disclosures Member of the speaker s bureau of Celgene and Janssen Advisory boards for Celgene, Janssen, BMS, Takeda, Amgen, Novartis, Karyopharm This presentation will discuss off-label use of myeloma drugs
26 Proportion Event-Free CLARION study KMP vs VMP Progression-Free Survival and Response rates Disease progression or death n (%) Median PFS months HR for KMP vs VMP (95% CI) KMP (n=478) 207 (43.3) ( ) 1-sided P=0.16 VMP (n=477) 214 (44.9) ORR; 84.3% KMP vs. 78.8% VMP CR; 25.9% KMP vs. 23.1% VMP Number at risk: KMP VMP KMP VMP Months Median follow-up time: 22.2 months for KMP and 21.6 months for VMP The absence of PFS difference was consistent across subgroups Facon et al, IMW meeting 2017, oral presentation 0 0
27 Continuing evolution of multiple myeloma treatment: selected new classes and targets st Generation novel agents 2 nd Generation novel therapies/immunotherapy Bortezomib Lenalidomide Thalidomide Bortezomib + Doxil Carfilzomib Pomalidomide Panobinostat Ixazomib Daratumumab Elotuzumab Atezolizumab* Durvalumab* Nivolumab* Pembrolizumab* AC-241/1215* CAR-T* Isatuximab* Vaccines* Marizomib* Oprozomib* 3 rd Generation IMiDs* Melflufen* Selinexor* Venetoclax* Nelfinavir* Proteasome inhibitor IMiD HDAC inhibitor Monoclonal antibody Targeted Therapy Adoptive T cell therapy Checkpoint inhibitors Vaccines IMiD, immunomodulatory drug; HDAC, histone deacetylase *Not yet FDA-approved for MM; available in clinical trials Adapted from Richardson PG. et al ASH 2015, MMRF 2016
28 Upcoming studies in frail patients
29 MAINTENANCE INDUCTION Trial Design MRC Myeloma XIV Transplant ineligible NDMM 1:1 Frailty Indexing (FI) performed in all patients at baseline Non-adjusted Frailty Index-adjusted Therapy 1:2 FIT UNFIT FRAIL CRDa IRDa 1:2 1:2 1:2 C 500mg D1 & D8 R 25mg D1-21 D 20mg I 4mg weekly CRDa IRDa CRDa IRDa CRDa FIT: C 500mg D1 & D8, R 25mg D1-21, D 20mg/wk, I 4mg/wk UNFIT: C 350mg D1 & D8, R 15mg D1-21, D 10mg/wk, I 3mg/wk FRAIL: C 250mg D1 & D8, R 10mg D1-21, D 10mg/wk, I 3mg/wk TREAT TO MAXIMUM RESPONSE (6-8 cycles) IRDa Revlimid 1:1 Ixazomib/Revlimid
30 Final Analysis of Overall Survival From the First Trial Thierry Facon, 1 Meletios A Dimopoulos, 2 Angela Dispenzieri, 3 John V Catalano, 4 Andrew Belch, 5 Michele Cavo, 6 Antonello Pinto, 7 Katja Weisel, 8 Heinz Ludwig, 9 Nizar J Bahlis, 10 Anne Banos, 11 Mourad Tiab, 12 Michel Delforge, 13 Jamie D Cavenagh, 14 Catarina Geraldes, 15 Je-Jung Lee, 16 Christine Chen, 17 Albert Oriol, 18 Javier De La Rubia, 19 Darrell White, 20 Daniel Binder, 21 Jin Lu, 22 Kenneth C Anderson, 23 Philippe Moreau, 24 Michel Attal, 25 Jean-Paul Fermand, 26 Herve Avet-Loiseau, 27 Annette Ervin-Haynes, 28 Guang Chen, 28 Vanessa Houck, 28 Cyrille Hulin, 29 and Lofti Benboubker 30 1 Service des Maladies du Sang, Hopital Claude Huriez, Lille, France; 2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; 3 Mayo Clinic, Rochester, MN; 4 Frankston Haematology and Oncology Center, Frankston, Australia; 5 Cross Cancer Institute, Edmonton, AB, Canada; 6 Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; 7 HematologyOncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy; 8 University of Tuebingen, Tuebingen, Germany; 9 Wilhelminen Cancer Research Institute, Department of Medicine, Center of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria; 10 University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada; 11 Centre Hospitalier de la Cote basque, Bayonne, France; 12 University Hospital, La Roche Sur Yon, France; 13 Department of Hematology, UZ Leuven, Leuven, Belgium; 14 Department of HaematoOncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom; 15 Hospitals da Universadade de Combra, Combra, Portugal; 16 Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea, The Republic of; 17 Princess Margaret Hospital, Toronto, ON, Canada; 18 Hospital Germans Trias i Pujol, Barcelona, Spain; 19 Hospital Universitari i Politècnic La Fe, Valencia, Spain; 20 QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada; 21 Kantonsspital Winterthur, Winterthur, CHE; 22 Peking University Institute of Hematology, Peking University People s Hospital, Beijing, China; 23 Harvard Medical School, DanaFarber Cancer Institute, Boston, MA; 24 University of Nantes, Nantes, France; 25 Institut Universitaire du Cancer de ToulouseOncopole, Toulouse, France; 26 Hopital SaintLouis, Paris, France; 27 Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France; 28 Celgene Corporation, Summit, NJ; 29 Bordeaux Hospital University Center (CHU), Bordeaux, France; 30 CHU Tours Hopital Bretonneau, Tours, France
31 msmart Off-Study Transplant Ineligible Standard-Risk Intermediate-Risk High-Risk t(11;14), t(6;14), Trisomies t(4;14) Del 17p, t(14;16), t(14;20) VRd for ~12 months; If age 75 or frail: Rd a VRd for ~12 months VRd c for ~12 months Rd x 1 year a, b Bortezomib-based maintenance for minimum of 1 year Bortezomib-based maintenance for minimum of 1 year a In patients treated initially with Rd, continuing treatment until progression is an option for patients responding well with low toxicities; b Dex is usually discontinued after first year c Clinical trials strongly recommended as the first option Dispenzieri et al. Mayo Clin Proc 2007;82: ; Kumar et al. Mayo Clin Proc : ; Mikhael et al. Mayo Clin Proc 2013;88: v14 //last reviewed July 2016
32 Mayo Clinic recommendations Initial Treatment of Myeloma Newly Diagnosed MM Not Transplant Candidate Transplant Candidate VRd x 4 cycles VRd Rd (if frail, age 75)* Auto SCT +/- Maintenance (Len for std risk; bortez for high risk) VRd x4 cycles Len maintenance Delayed Transplant *Frailty Score; Palumbo A, Blood. 2015;125: ; VCD x 12 months is alternative Rajkumar SV. 2016
33 Conclusion Assessment of fitness and frailty is highly relevant for optimal treatment selection Fit elderly patients usually tolerate more aggressive treatments including triple combinations Carefully selected fit elderly patients may be candidates for high-dose melphalan followed by autologous transplantation
34 IMW MM Frailty Score Variable HR (CI 95%) P SCORE AGE Age <75 years 1-0 Age years 1.13 ( ) Age >80 years 2.40 ( ) < CHARLSON INDEX Charlson <1 1-0 Charlson > ( ) ADL SCORE ADL >4 1-0 ADL< ( ) IADL SCORE IADL >5 1-0 IADL< ( ) ADDITIVE TOTAL SCORE PATIENT STATUS % 0 FIT 39% 1 INTERMEDIATE 31% >2 FRAIL 30% Palumbo A et al, Blood 25(13): , 2015
35 Cumulative Incidence of Treatment Discontinuation by Frailty Level 1.0 Product-Limit Survival Estimates With Number of Subjects at Risk + Censored Logrank p= Survival Probability Fitness Status 12 Month 18 Month NON-FRAIL FRAIL NON-FRAIL FRAIL TTD (months) 2016 fitstat5 NON-FRAIL FRAIL Median Subjects Event Censored Survival 95% CL NON-FRAIL FRAIL Comparison HazardRatio pvalue CI_Lower CI_Upper non-frail vs Frail
36 Patients IFM MM-020- FIRST; Response ITT population (%) 81% 79% 67% 33% 31% 37% 27% 27% 21% 20% 18% 12% Hulin C, et al. J Clin Oncol 2016 Jun 20; DOI: /JCO [Epub ahead of print]
37 FIRST Trial: Impact of Response Cumulative Response Rate by Tx Month Of pts who achieved VGPR, 13.2% vs 2.7% achieved VGPR beyond 18 mos of Tx in the Rd continuous and Rd18 arms, respectively Rd Continuous Arm a Rd18 Arm a a Percentage shown is for pts achieving VGPR or better in the current month. pt, patient; Rd continuous, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide and low-dose dexamethasone for 18 cycles; Tx, treatment; VGPR, very good partial response. Reprinted from Bahlis NJ, et al. Leukemia Apr 28. [Epub ahead of print]. Creative Commons Attribution 4.0 International License (
38 ESMO Guideline usual dosing schedule
39 Myeloma XI trial outline R 1:1 Induction 1 Induction 2 Maintenance CTD CRD Max. response PD SD MR PR VGPR CR R 1:1 CVD No CVD ASCT (if TE) R 1:1 Lenalidomide Observation
40 Myeloma XI - Lenalidomide Maintenance Induction Maintenance Induction 1; CTD vs.crd- Induction 2; CVD vs no CVD N=1551 TE=828; TNE=723 Median follow-up: 27 months (IQR 13 43) Exclusion criteria NDMM Treated on Myeloma XI induction protocols Failure to respond to lenalidomide as induction IMiD, or development of PD Previous or concurrent active malignancies R 1:1 Lenalidomide 10 mg/day, days 1 21/28 Observation IQR, interquartile range; NDMM, newly diagnosed multiple myeloma; PD, progressive disease
41 Patients alive and progression-free (%) Transplant non-eligible pathway Significant improvement in PFS from 11 to 24 months, HR= Median PFS, months [95% CI] Lenalidomide (n=406) 24 [21, 30] Observation (n=317) 11 [9, 13] Time since randomisation (months) No. of patients at risk: Lenalidomide Observation
42 FIRST (MM-020): Final Survival Analysis Time to Next Anti-Myeloma Treatment Rd continuous extended the median TTNT compared with MPT Median TTNT was also longer in patients who achieved CR/VGPR Subgroup Rd continuous vs MPT HR & 95% CI Median TTNT (mos) Rd continuous Rd18 MPT Rd continuous vs MPT HR (95% CI) IT T C R /V G P R P R ( ) ( ) ( ) Favors Rd Continuous Favors MPT CR, complete response; FIRST, Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide; HR, hazard ratio; ITT, intent to treat population; MPT, melphalan, prednisone, thalidomide; PR, partial response; Rd continuous, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; TTNT, time to next anti-myeloma treatment; VGPR, very good partial response. Facon T, et al. Final Analysis of Overall Survival From the FIRST Trial. ASH 2016, abstract 241.
COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationCurrent treatment practices in Multiple Myeloma / 2017
Current treatment practices in Multiple Myeloma / 2017 Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Historique du traitement du Myélome Multiple
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationAbstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationMultiple Myeloma New Trials and New Drugs. Rafat Abonour, M.D.
Multiple Myeloma New Trials and New Drugs Rafat Abonour, M.D. Treatment Combinations Then and Now NEW VD Rev/Dex CyBorD VTD VRD CDR SCT VD/VRD Lenalidomide Bortezomib Bortezomib Lenalidomide Thalidomide
More informationUpcoming Therapies for Myeloma in Alberta. Dr Christopher Venner Cross Cancer Institute
Upcoming Therapies for Myeloma in Alberta Dr Christopher Venner Cross Cancer Institute Outline Diagnosis Hope for earlier diagnosis Prognosis Update in staging system for modern era highlights clear improvements
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationMultiple Myeloma in 2017 Making Sense of All of the Choices
Multiple Myeloma in 2017 Making Sense of All of the Choices TACOS March 2017 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Associate Dean, Mayo School
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationNew myeloma drugs improve response and extend survival
The JCSO Interview New myeloma drugs improve response and extend survival David H Henry, MD, a interviews Kenneth C Anderson, MD b a Department of Medicine, University of Pennsylvania Perelman School of
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationAn Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
An Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma Philippe Moreau, MD; Maria-Victoria Mateos, MD, PhD; Joan Bladé,MD; Lotfi
More information